Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: A systematic review

Wei Bao, Aileen Baecker, Yiqing Song, Michele Kiely, Simin Liu, Cuilin Zhang

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Objective We aimed to systematically review available literature linking adipokines to gestational diabetes mellitus (GDM) for a comprehensive understanding of the roles of adipokines in the development of GDM. Methods We searched PubMed/MEDLINE and EMBASE databases for published studies on adipokines and GDM through October 21, 2014. We included articles if they had a prospective study design (i.e., blood samples for adipokines measurement were collected before GDM diagnosis). Random-effects models were used to pool the weighted mean differences comparing levels of adipokines between GDM cases and non-GDM controls. Results Of 1523 potentially relevant articles, we included 25 prospective studies relating adipokines to incident GDM. Our meta-analysis of nine prospective studies on adiponectin and eight prospective studies on leptin indicated that adiponectin levels in the first or early second trimester of pregnancy were 2.25 μg/ml lower (95% CI: 1.75-2.75), whereas leptin levels were 7.25 ng/ml higher (95% CI 3.27-11.22), among women who later developed GDM than women who did not. Prospective data were sparse and findings were inconsistent for visfatin, retinol binding protein (RBP-4), resistin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and vaspin. We did not identify prospective studies for several novel adipokines, including chemerin, apelin, omentin, or adipocyte fatty acid-binding protein. Moreover, no published prospective studies with longitudinal assessment of adipokines and incident GDM were identified. Conclusion Adiponectin levels in the first or second trimester of pregnancy are lower among pregnant women who later develop GDM than non-GDM women, whereas leptin levels are higher. Well-designed prospective studies with longitudinal assessment of adipokines during pregnancy are needed to understand the trajectories and dynamic associations of adipokines with GDM risk.

Original languageEnglish (US)
Pages (from-to)756-764
Number of pages9
JournalMetabolism: Clinical and Experimental
Volume64
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Adipokines
Gestational Diabetes
Second Pregnancy Trimester
Prospective Studies
Adiponectin
Leptin
Diabetes Mellitus
Nicotinamide Phosphoribosyltransferase
Resistin
Retinol-Binding Proteins
Fatty Acid-Binding Proteins
Pregnancy
First Pregnancy Trimester
Adipocytes
PubMed
MEDLINE
Meta-Analysis
Pregnant Women
Interleukin-6
Tumor Necrosis Factor-alpha

Keywords

  • Adipokines
  • Adiponectin
  • Gestational diabetes mellitus
  • Leptin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus : A systematic review. / Bao, Wei; Baecker, Aileen; Song, Yiqing; Kiely, Michele; Liu, Simin; Zhang, Cuilin.

In: Metabolism: Clinical and Experimental, Vol. 64, No. 6, 01.01.2015, p. 756-764.

Research output: Contribution to journalArticle

@article{86b7e714dda7423aae292934ddb5f6dc,
title = "Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: A systematic review",
abstract = "Objective We aimed to systematically review available literature linking adipokines to gestational diabetes mellitus (GDM) for a comprehensive understanding of the roles of adipokines in the development of GDM. Methods We searched PubMed/MEDLINE and EMBASE databases for published studies on adipokines and GDM through October 21, 2014. We included articles if they had a prospective study design (i.e., blood samples for adipokines measurement were collected before GDM diagnosis). Random-effects models were used to pool the weighted mean differences comparing levels of adipokines between GDM cases and non-GDM controls. Results Of 1523 potentially relevant articles, we included 25 prospective studies relating adipokines to incident GDM. Our meta-analysis of nine prospective studies on adiponectin and eight prospective studies on leptin indicated that adiponectin levels in the first or early second trimester of pregnancy were 2.25 μg/ml lower (95{\%} CI: 1.75-2.75), whereas leptin levels were 7.25 ng/ml higher (95{\%} CI 3.27-11.22), among women who later developed GDM than women who did not. Prospective data were sparse and findings were inconsistent for visfatin, retinol binding protein (RBP-4), resistin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and vaspin. We did not identify prospective studies for several novel adipokines, including chemerin, apelin, omentin, or adipocyte fatty acid-binding protein. Moreover, no published prospective studies with longitudinal assessment of adipokines and incident GDM were identified. Conclusion Adiponectin levels in the first or second trimester of pregnancy are lower among pregnant women who later develop GDM than non-GDM women, whereas leptin levels are higher. Well-designed prospective studies with longitudinal assessment of adipokines during pregnancy are needed to understand the trajectories and dynamic associations of adipokines with GDM risk.",
keywords = "Adipokines, Adiponectin, Gestational diabetes mellitus, Leptin",
author = "Wei Bao and Aileen Baecker and Yiqing Song and Michele Kiely and Simin Liu and Cuilin Zhang",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2015.01.013",
language = "English (US)",
volume = "64",
pages = "756--764",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus

T2 - A systematic review

AU - Bao, Wei

AU - Baecker, Aileen

AU - Song, Yiqing

AU - Kiely, Michele

AU - Liu, Simin

AU - Zhang, Cuilin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective We aimed to systematically review available literature linking adipokines to gestational diabetes mellitus (GDM) for a comprehensive understanding of the roles of adipokines in the development of GDM. Methods We searched PubMed/MEDLINE and EMBASE databases for published studies on adipokines and GDM through October 21, 2014. We included articles if they had a prospective study design (i.e., blood samples for adipokines measurement were collected before GDM diagnosis). Random-effects models were used to pool the weighted mean differences comparing levels of adipokines between GDM cases and non-GDM controls. Results Of 1523 potentially relevant articles, we included 25 prospective studies relating adipokines to incident GDM. Our meta-analysis of nine prospective studies on adiponectin and eight prospective studies on leptin indicated that adiponectin levels in the first or early second trimester of pregnancy were 2.25 μg/ml lower (95% CI: 1.75-2.75), whereas leptin levels were 7.25 ng/ml higher (95% CI 3.27-11.22), among women who later developed GDM than women who did not. Prospective data were sparse and findings were inconsistent for visfatin, retinol binding protein (RBP-4), resistin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and vaspin. We did not identify prospective studies for several novel adipokines, including chemerin, apelin, omentin, or adipocyte fatty acid-binding protein. Moreover, no published prospective studies with longitudinal assessment of adipokines and incident GDM were identified. Conclusion Adiponectin levels in the first or second trimester of pregnancy are lower among pregnant women who later develop GDM than non-GDM women, whereas leptin levels are higher. Well-designed prospective studies with longitudinal assessment of adipokines during pregnancy are needed to understand the trajectories and dynamic associations of adipokines with GDM risk.

AB - Objective We aimed to systematically review available literature linking adipokines to gestational diabetes mellitus (GDM) for a comprehensive understanding of the roles of adipokines in the development of GDM. Methods We searched PubMed/MEDLINE and EMBASE databases for published studies on adipokines and GDM through October 21, 2014. We included articles if they had a prospective study design (i.e., blood samples for adipokines measurement were collected before GDM diagnosis). Random-effects models were used to pool the weighted mean differences comparing levels of adipokines between GDM cases and non-GDM controls. Results Of 1523 potentially relevant articles, we included 25 prospective studies relating adipokines to incident GDM. Our meta-analysis of nine prospective studies on adiponectin and eight prospective studies on leptin indicated that adiponectin levels in the first or early second trimester of pregnancy were 2.25 μg/ml lower (95% CI: 1.75-2.75), whereas leptin levels were 7.25 ng/ml higher (95% CI 3.27-11.22), among women who later developed GDM than women who did not. Prospective data were sparse and findings were inconsistent for visfatin, retinol binding protein (RBP-4), resistin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and vaspin. We did not identify prospective studies for several novel adipokines, including chemerin, apelin, omentin, or adipocyte fatty acid-binding protein. Moreover, no published prospective studies with longitudinal assessment of adipokines and incident GDM were identified. Conclusion Adiponectin levels in the first or second trimester of pregnancy are lower among pregnant women who later develop GDM than non-GDM women, whereas leptin levels are higher. Well-designed prospective studies with longitudinal assessment of adipokines during pregnancy are needed to understand the trajectories and dynamic associations of adipokines with GDM risk.

KW - Adipokines

KW - Adiponectin

KW - Gestational diabetes mellitus

KW - Leptin

UR - http://www.scopus.com/inward/record.url?scp=84927974962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927974962&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2015.01.013

DO - 10.1016/j.metabol.2015.01.013

M3 - Article

C2 - 25749468

AN - SCOPUS:84927974962

VL - 64

SP - 756

EP - 764

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -